| Abbreviation | Full name |
| ABPI | Association of British Pharmaceutical Industry |
| AfPA | Alliance for Patient Access |
| BAP | Biosimilars Action Plan |
| BLA | Biologics License Application |
| BPC | Biologics Prescribers Collaborative |
| BPCI Act | Biologics Price Competition and Innovation Act |
| CAR‐T | Chimeric Antigen Receptor Therapy |
| CHMP | Committee for Medicinal Products for Human Use (EMA) |
| CIOMS | Council of International Organizations of Medical Sciences |
| CQAs | Critical Quality Attributes |
| CVMP | Committee for Medicinal Products for Veterinary Use |
| Da | Dalton |
| DNA | Deoxyribonucleic Acid |
| EMA | European Medicines Agency |
| EPAR | European Public Assessment Report |
| EU | European Union |
| FDA | Food and Drug Administration |
| GABi/GaBI | Generics and Biosimilars Initiative |
| LDN | Limited Distribution Network |
| mAbs | monoclonal Antibodies |
| NHS | National Health Service |
| NICE | National Institute for Clinical Excellence |
| NMS | Non‐Medical Switching |
| NOBs | Non‐Original Biologics |
| PBS | Pharmaceutical Benefits Scheme |
| P&T | Pharmacy & Therapeutics (Committee) |
| PTMs | Post‐Translational Modifications |
| QbD | Quality by Design |
| QUM | Quality Use of Medicine |
| RMP | Risk Management Plan |
| RPS | Reference Product Sponsor |
| RWE | Real‐World Evidence |
| SEBs | Subsequent‐Entry Biologics |
| SMD | Small Molecule Drug |
| UMC | Uppsala Monitoring Centre |
| UNESCO | United Nations Educational, Scientific and Cultural Organization |
| USA | United States of America |
| USD | US Dollar |
| WHO | World Health Organisation |
